Biotech & Pharma

Pricing Policy Has Become the Primary Structural Constraint on Pharma Revenue

The IRA's Medicare price negotiation cascade, MFN executive orders, and new CMS mandatory pricing models (GLOBE, GUARD) are hitting multiple companies simultaneously: Merck faces negotiated pricing on Januvia, Janumet, Lenvima, and expects Keytruda (49% of total 2025 sales) to be selected in 2027; Sanofi signed a voluntary MFN agreement committing to 61% price cuts on legacy portfolio drugs; and Novo Nordisk's three core semaglutide products entered the second round of Medicare price negotiations. Sanofi's filing explicitly states this environment 'will continue to exert unprecedented price pressure that will compress margins and shorten product lifecycles,' and the CBO projects IRA-driven federal drug spending cuts of $290 billion over the next decade. The policy mechanism is no longer a future risk: it is an active revenue compression event reshaping capital allocation across every large-cap in the sector.

GLP-1 Leadership Is Fragmenting as Competition Intensifies Across All Delivery Formats

Novo Nordisk lost the leading total weekly prescription position for Wegovy in obesity and for Ozempic in type 2 diabetes in the US to a single competing product in early 2025, the first time both flagship franchises ceded leadership concurrently. Eli Lilly's revenue grew 44.7% year-over-year in FY2025 to $65.18B, the largest absolute growth among all tracked companies, driven by GLP-1 commercial momentum. Pfizer entered the obesity space by acquiring Metsera for $8.0 billion, and Regeneron in-licensed HS-20094, a dual GLP-1/GIP receptor agonist, marking the company's first explicit entry into GLP-1 combination therapy. The competitive frontier is shifting from injectable volume share to oral formulations, combination mechanisms, and comorbidity adjacencies.

Gene Editing and RNA Therapies Are Crossing from Clinical to Regulatory and Commercial

Beam Therapeutics completed enrollment and manufacturing for its BEACON trial and set a BLA submission target for risto-cel as early as year-end 2026; Intellia secured a $400 million milestone-linked debt facility with FDA approval of lonvo-z as an explicit capital trigger; and Alnylam's revenue grew 65.2% year-over-year in FY2025 to $3.71B, the fastest top-line growth among commercialized therapeutic platforms in the tracked set. The language across this cohort has crossed a threshold: 'enrollment ongoing' and 'IND planned' are being replaced by 'BLA submission target,' 'FDA alignment on accelerated approval pathway,' and 'non-dilutive financing enables lonvo-z launch.' These programs are no longer in de-risking mode; they are in regulatory and commercial execution mode.

M&A Has Become the Primary Pipeline Mechanism for Large-Cap Biotechs

Eli Lilly completed five acquisitions (Orna, Centessa, Kelonia, Ventyx, Ajax) for $13.3 billion in H1 2026 alone, and announced pending acquisitions totaling up to $12 billion in potential payable amounts, deploying capital at a pace that internal R&D cannot match. AbbVie acquired Apogee Therapeutics for $10.9 billion and Capstan Therapeutics for $2.1 billion while simultaneously acquiring RC148 from RemeGen for $650 million upfront, building an immunology pipeline through external sourcing. Gilead acquired Arcellx for $7.8 billion and Tubulis for $3.15 billion in the same cycle, broadening into CAR-T and ADC from its established antiviral base. The convergence of biosimilar cliff exposure, IRA pricing pressure, and near-term patent expiry is forcing companies to buy commercial-stage or late-clinical assets rather than wait for internal development timelines.